TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Philippe Armand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.